Respiratory diseases are one of the leading causes of morbidity and mortality worldwide. The current pandemic has further highlighted the importance of respiratory health. The human respiratory system is complex, and there are several factors that affect drug delivery to the lungs. Respiratory drug delivery formulation is an essential aspect of treating respiratory conditions, and it has seen several advancements over the years.
Advancements in Respiratory Drug Delivery Formulation
Drug formulation for respiratory drug delivery has come a long way from traditional nebulizers and metered dose inhalers. Newer technologies have led to the development of dry powder inhalers (DPIs), which have improved the delivery of drugs to the lungs. DPIs are portable, easy to use, and have better stability compared to nebulizers and metered dose inhalers. Moreover, DPIs do not require the use of propellants, which is beneficial for the environment.
Particle engineering has also played a significant role in the development of respiratory drug delivery formulations. Particle size and shape can impact drug deposition in the respiratory tract. The use of nano and micro-particulate systems has shown promising results in improving drug delivery to the lungs. The use of nanotechnology has also enabled targeted delivery of drugs to specific regions of the lungs.
Factors Affecting Respiratory Drug Delivery Formulation
Several factors affect respiratory drug delivery formulation, including the physicochemical properties of the drug, the inhalation device, and the patient's ability to use the device correctly. The physicochemical properties of the drug, such as solubility and stability, affect the formulation of the drug. A drug that is not soluble in water may require a different formulation than a drug that is soluble.
The inhalation device also plays a crucial role in respiratory drug delivery. DPIs, nebulizers, and metered dose inhalers all have different mechanisms of drug delivery, and each has its benefits and limitations. Moreover, the size and shape of the inhalation device can affect the deposition of the drug in the lungs.
The patient's ability to use the inhalation device correctly is also essential for effective drug delivery. Patients must receive proper education on how to use the device to ensure proper drug delivery to the lungs. Factors such as age, respiratory function, and cognitive ability can also affect a patient's ability to use the device correctly.
Conclusion
Respiratory drug delivery formulation is an essential aspect of treating respiratory conditions. Advancements in drug formulation, delivery devices, and inhalation technologies have improved drug delivery to the lungs. Particle engineering and nanotechnology have enabled targeted drug delivery to specific regions of the lungs. Factors such as drug physicochemical properties, inhalation device, and patient ability to use the device correctly all play a crucial role in respiratory drug delivery formulation. With continued research and development, respiratory drug delivery formulation will continue to improve, providing better treatment options for patients with respiratory conditions.
Get More Insights, Click Here: https://www.coherentmarketinsights.com/market-insight/respiratory-drug-delivery-formulation-market-2649
Increasing preference of pulmonary route of drug delivery, increasing technological developments in the form of smart/digital inhalers and rising incidences of respiratory diseases such as COPD, asthma, and cystic fibrosis.Global respiratory drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5%.
Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD).Emerging markets such as India, China, & Japan and growth in online marketing channels are expected to offer lucrative growth opportunities for market players in the coming years.
On the other hand, factors such as regulatory issues and pricing pressures are the major factors restraining Respiratory Drug Delivery market growth.The pulmonary drug delivery market is segmented based on formulations, canister type, applications, end users, and regions.
On the basis of end user, the market is segmented into hospitals & clinics and homecare settings.
The hospitals & clinics segment dominated the market in 2016, this is attributed to the increasing incidence of diseases such as pneumonia and acute exacerbation of COPD (AECOPD) is driving the number of hospitalizations each year.Based on canister type, the Respiratory Drug Delivery Market is segmented into plain and coated canister.
The coated canister segment is expected to be the fastest growing market in canister type segments in the respiratory Drug Delivery Market during the forecast period.
